X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (795) 795
humans (694) 694
male (672) 672
neurokinin-1 receptor antagonists (622) 622
index medicus (583) 583
pharmacology & pharmacy (494) 494
substance p (390) 390
female (354) 354
rats (337) 337
receptors, neurokinin-1 - metabolism (329) 329
substance-p (314) 314
neurosciences (260) 260
antiemetics - therapeutic use (233) 233
vomiting - chemically induced (219) 219
mice (216) 216
neurokinin-1 receptor (202) 202
aprepitant (198) 198
adult (179) 179
antineoplastic agents - adverse effects (177) 177
substance p - metabolism (177) 177
nausea - chemically induced (176) 176
oncology (176) 176
middle aged (173) 173
substance p - pharmacology (173) 173
dose-response relationship, drug (166) 166
double-blind (166) 166
vomiting - prevention & control (159) 159
piperidines - pharmacology (158) 158
nausea (154) 154
morpholines - therapeutic use (153) 153
prevention (151) 151
cancer (148) 148
chemotherapy (148) 148
receptors, neurokinin-1 - physiology (144) 144
rats, sprague-dawley (140) 140
nausea - prevention & control (130) 130
nk1 receptor (127) 127
neurokinin-1 receptor antagonists - therapeutic use (119) 119
tachykinins (119) 119
inflammation (116) 116
rats, wistar (115) 115
receptors, neurokinin-1 - genetics (114) 114
vomiting (113) 113
vomiting - drug therapy (113) 113
disease models, animal (110) 110
aged (108) 108
analysis (108) 108
placebo-controlled trial (106) 106
research (100) 100
receptor (99) 99
neuropeptides (95) 95
neurokinin (94) 94
neoplasms - drug therapy (93) 93
substance p - analogs & derivatives (93) 93
biochemistry & molecular biology (92) 92
guinea pigs (92) 92
substance p - antagonists & inhibitors (92) 92
medicine & public health (89) 89
chemotherapy-induced nausea (87) 87
double-blind method (87) 87
moderately emetogenic chemotherapy (87) 87
morpholines - pharmacology (87) 87
nausea - drug therapy (85) 85
in vitro techniques (83) 83
treatment outcome (83) 83
receptors, neurokinin-1 - drug effects (81) 81
receptors, neurokinin-2 - antagonists & inhibitors (80) 80
antiemetics - pharmacology (79) 79
neurons (79) 79
receptor antagonist (79) 79
dexamethasone (78) 78
drug therapy, combination (78) 78
psychiatry (78) 78
tachykinin nk1 receptor (78) 78
tachykinin receptors (78) 78
receptors (77) 77
care and treatment (76) 76
rat (76) 76
cisplatin-induced emesis (75) 75
time factors (75) 75
expression (73) 73
substance p - physiology (73) 73
article (72) 72
mice, inbred c57bl (72) 72
efficacy (71) 71
antagonist (70) 70
gene-related peptide (70) 70
pain (70) 70
antiemetics (69) 69
tachykinin (69) 69
brain (67) 67
chemotherapy-induced nausea and vomiting (67) 67
antagonists (66) 66
high-dose cisplatin (66) 66
neurokinin-1 receptor antagonists - pharmacology (66) 66
peptide fragments - pharmacology (66) 66
pharmacology (66) 66
antiemetics - administration & dosage (65) 65
piperidines - therapeutic use (63) 63
clinical neurology (62) 62
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1306) 1306
Japanese (17) 17
German (7) 7
French (4) 4
Chinese (3) 3
Hungarian (2) 2
Spanish (2) 2
Danish (1) 1
Dutch (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the National Cancer Institute, ISSN 0027-8874, 09/2012, Volume 104, Issue 17, pp. 1280 - 1292
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 11/2015, Volume 23, Issue 11, pp. 3281 - 3288
Journal Article
Cancer, ISSN 0008-543X, 08/2016, Volume 122, Issue 15, pp. 2418 - 2425
BACKGROUND Rolapitant, a novel neurokinin‐1 receptor antagonist, provided effective protection against chemotherapy‐induced nausea and vomiting (CINV) in a... 
moderately emetogenic chemotherapy | chemotherapy‐induced nausea and vomiting | carboplatin | neurokinin‐1 receptor antagonist | rolapitant | Carboplatin | Moderately emetogenic chemotherapy | Rolapitant | Neurokinin-1 receptor antagonist | Chemotherapy-induced nausea and vomiting | GUIDELINE UPDATE | SAFETY | APREPITANT | neurokinin-1 receptor antagonist | CELL LUNG-CANCER | TRIAL | PATTERN | ONCOLOGY | DOUBLE-BLIND | EMESIS | chemotherapy-induced nausea and vomiting | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Spiro Compounds - therapeutic use | Spiro Compounds - adverse effects | Carboplatin - adverse effects | Neoplasms - complications | Aged, 80 and over | Adult | Female | Nausea - drug therapy | Vomiting - prevention & control | Neurokinin-1 Receptor Antagonists - adverse effects | Chemoprevention | Neurokinin-1 Receptor Antagonists - therapeutic use | Risk Factors | Carboplatin - administration & dosage | Neoplasms - mortality | Treatment Outcome | Vomiting - drug therapy | Neoplasms - drug therapy | Nausea - prevention & control | Nausea - etiology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vomiting - etiology | Aged | Complications and side effects | Care and treatment | Chemotherapy | Nausea | Dosage and administration | Cancer | Original
Journal Article
Science Translational Medicine, ISSN 1946-6234, 05/2017, Volume 9, Issue 392, p. eaal3447
Journal Article
Journal Article
Journal of Pain and Symptom Management, ISSN 0885-3924, 2014, Volume 47, Issue 3, pp. 542 - 550
Journal Article